Stifel on Biogen (BIIB): Apellis acquisition 'surprising,' but makes sense given move towards rare kidney
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $214.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "Biogen's acquisition ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
